Autopsy report · NCT00455429
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
Cause of deathSafety
“The study was stopped due to a non-clinical safety finding.”
Life of this trial
- Ran for about 1 year 11 months before it stopped.
- 84 participants enrolled.
- Results were posted on the registry 4 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Industry
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo; JNJ-26113100 (50 mg) once daily; JNJ-26113100 (100 mg) once daily; JNJ-26113100 (100 mg) twice daily; JNJ-26113100 (250 mg) twice daily
- Participants
- 84
- Sites
- 19
- Countries
- United States
Trials that died the same way
- Stroke With Transfusions Changing to Hydroxyurea
“The study has been stopped due to safety and futility concerns.” - Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
“The study was stopped due to safety concerns” - Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
“study was stopped for business/administrative reasons and not for patient safety concerns” - A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
“This study was terminated due to lack of clinical activity and not due to safety reasons.” - Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery
“The study was stopped due to difficulties in including patients”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.